Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Steven Speiser

Psychiatry Kissimmee, FL Medical Doctor

NPI 1598709990 CMS profile 550786

206 Park Place Blvd, Kissimmee, FL 34741

Open in the dashboard

General payments

$7,928

339 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Steven Speiser of Kissimmee, FL is reported in the CMS Open Payments database as having received $7,928 across 339 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $374 11
2022 General $1,967 76
2021 General $2,864 118
2020 General $1,077 65
2019 General $1,646 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Speiser
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Steven Speiser were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Steven Speiser Psychiatry median Middle half National median
2019 $1,646 $184 $59–$605 $163
2020 $1,077 $119 $36–$372 $114
2021 $2,864 $143 $43–$576 $132
2022 $1,967 $153 $50–$590 $149
2023 $374 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $1,651 78 payments
  2. Alkermes, Inc. $1,585 68 payments
  3. Otsuka America Pharmaceutical, Inc. $1,072 57 payments
  4. AbbVie, Inc. $852 29 payments
  5. Indivior Inc. $557 26 payments
  6. Teva Pharmaceuticals USA, Inc. $427 5 payments
  7. Vanda Pharmaceuticals Inc. $401 24 payments
  8. Sunovion Pharmaceuticals Inc. $367 12 payments
  9. Otsuka Pharmaceutical Development & Commercialization, Inc. $343 3 payments
  10. ITI, Inc. $241 15 payments
  11. Other $433 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,881 338 payments
  2. Education $47 1 payment
Products named General payments · program years 2019–2023
  1. INVEGA SUSTENNA $1,661 77 payments
  2. ARISTADA Cns $1,310 63 payments
  3. ARISTADA Cns $1,310 63 payments
  4. ARISTADA INITIO $1,284 62 payments
  5. ARISTADA Cns $1,121 51 payments
  6. ARISTADA Cns $1,121 51 payments
  7. ABILIFY MAINTENA $938 54 payments
  8. VRAYLAR $852 29 payments
  9. INVEGA TRINZA $702 36 payments
  10. PERSERIS $547 25 payments
  11. Other $4,209 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

339 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record